AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34972609 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume challenge (200 ml saline in 20 s)
Number of subjects: 32
Study 34972665 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRS-IVUS imaging at baseline
Number of subjects: 73
Study 34972665 — intervention group
Group type: COMPARATOR
Intervention: No imaging at baseline
Number of subjects: 73
Study 34972769 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined assessment of circulating biomarkers (circulating tumour DNA, cell-free methylated DNA, circulating proteins) and radiomic variables
Number of subjects: 750
Study 34972769 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood and urine samples from patients with stage I-IIA BC
Number of subjects: 750
Study 34972769 — intervention group
Group type: COMPARATOR
Intervention: Blood and urine samples from patients with benign lesions and healthy controls
Number of subjects: 750
Study 34972822 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (part of a double-blind, randomized iron intervention trial)
Number of subjects: 616
Study 34972827 — intervention group
Group type: EXPERIMENTAL
Intervention: Real time laser-doppler flowmetry (LDF) and white light spectrophotometry (WLS) used for assessment of microcirculatory oxygen delivery and uptake before and after forearm ischemia.
Number of subjects: 60
Study 34972827 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 60
Study 34972827 — intervention group
Group type: EXPERIMENTAL
Intervention: Septic shock patients
Number of subjects: 60
Study 34973077 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5→10 mg BID (Dose-up)
Number of subjects: 0
Study 34973077 — intervention group
Group type: COMPARATOR
Intervention: Tofacitinib 5 mg BID (Stay-on 5)
Number of subjects: 0
Study 34973077 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10→5 mg BID (Dose-down)
Number of subjects: 0
Study 34973077 — intervention group
Group type: COMPARATOR
Intervention: Tofacitinib 10 mg BID (Stay-on 10)
Number of subjects: 0
Study 34973207 — intervention group
Group type: EXPERIMENTAL
Intervention: Etonogestrel implants
Number of subjects: 20
Study 34973418 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic navigation bronchoscopy (ENB) using superDimension navigation system versions 6.3 to 7.1
Number of subjects: 1388
Study 34973418 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic navigation bronchoscopy (ENB)
Number of subjects: 1388
Study 34973601 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic ketamine treatment
Number of subjects: 0
Study 34973601 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34974364 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-FFR-D (diastolic phase)
Number of subjects: 151
Study 34974364 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-FFR-S (systolic phase)
Number of subjects: 151
Study 34974453 — intervention group
Group type: EXPERIMENTAL
Intervention: Homologous third dose of inactivated whole-virion vaccine
Number of subjects: 0
Study 34974510 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (2 mg) with a treat-and-extend regimen
Number of subjects: 45
Study 34974659 — intervention group
Group type: EXPERIMENTAL
Intervention: Precautionary behavior during COVID-19 pandemic
Number of subjects: 306
Study 34974659 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise
Number of subjects: 306
Study 34974659 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher CCI status
Number of subjects: 306
Study 34974659 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and income levels
Number of subjects: 306
Study 34974918 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-facilitated Screening and provider Brief Advice (cSBA)
Number of subjects: 2096
Study 34974918 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 2096
Study 34975369 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chronic pain
Number of subjects: 0
Study 34975369 — intervention group
Group type: COMPARATOR
Intervention: No preoperative chronic pain
Number of subjects: 0
Study 34975713 — intervention group
Group type: EXPERIMENTAL
Intervention: FES-assisted cycling training (40 min/session, 3-5 sessions/week for 20 sessions)
Number of subjects: 15
Study 34975713 — intervention group
Group type: EXPERIMENTAL
Intervention: FES-assisted cycling training
Number of subjects: 15
Study 34975844 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic Vγ9Vδ2 T-cell therapy adjunct with anti-TB drugs
Number of subjects: 8
Study 34976286 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (24 U)
Number of subjects: 417
Study 34976286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417
Study 34976290 — intervention group
Group type: EXPERIMENTAL
Intervention: VP-102 (Cantharidin, 0.7% w/v)
Number of subjects: 0
Study 34976290 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 34976630 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-HPV (home-based Human Papillomavirus self-sampling)
Number of subjects: 127
Study 34976630 — intervention group
Group type: COMPARATOR
Intervention: Dr-HPV (HPV performed by the physician)
Number of subjects: 127
Study 34976630 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-HPV
Number of subjects: 127
Study 34976830 — intervention group
Group type: EXPERIMENTAL
Intervention: AdHER2 DC vaccine
Number of subjects: 33
Study 34977109 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplementation
Number of subjects: 0
Study 34977109 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 0
Study 34977512 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh lemon juice supplementation (60 mL twice daily)
Number of subjects: 203
Study 34977512 — intervention group
Group type: COMPARATOR
Intervention: No supplementation (control)
Number of subjects: 203
Study 34977516 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-Gaming
Number of subjects: 193
Study 34977516 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Gaming
Number of subjects: 193
Study 34977516 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 193
Study 34977519 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegbelfermin (PGBF)
Number of subjects: 2
Study 34977519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 34977602 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of SARS-CoV-2 vaccines
Number of subjects: 90
Study 34977602 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of SARS-CoV-2 vaccines
Number of subjects: 90
Study 34977602 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls receiving two doses of SARS-CoV-2 vaccines
Number of subjects: 90
Study 34977838 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Measures based on WHO Standards
Number of subjects: 21027
Study 34977972 — intervention group
Group type: EXPERIMENTAL
Intervention: Erdafitinib 6-mg/day
Number of subjects: 156
Study 34977972 — intervention group
Group type: EXPERIMENTAL
Intervention: Erdafitinib 8-mg/day
Number of subjects: 156
Study 34977972 — intervention group
Group type: EXPERIMENTAL
Intervention: Erdafitinib (both doses)
Number of subjects: 156
Study 34977985 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 122
Study 34977986 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 107
Study 34978027 — intervention group
Group type: EXPERIMENTAL
Intervention: Eliapixant (P2X3 receptor antagonist)
Number of subjects: 0
Study 34978544 — intervention group
Group type: EXPERIMENTAL
Intervention: Support person present
Number of subjects: 76
Study 34978544 — intervention group
Group type: COMPARATOR
Intervention: No support person
Number of subjects: 76
Study 34978580 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-contrast 3D T1-weighted images using FreeSurfer
Number of subjects: 22
Study 34978580 — intervention group
Group type: COMPARATOR
Intervention: Pre-contrast 3D T1-weighted images using FreeSurfer
Number of subjects: 22
Study 34978654 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBP™ (optical smartphone application)
Number of subjects: 101
Study 34978656 — intervention group
Group type: EXPERIMENTAL
Intervention: ZHF sensors
Number of subjects: 60
Study 34978656 — intervention group
Group type: EXPERIMENTAL
Intervention: DS sensors
Number of subjects: 60
Study 34978890 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly long-acting cabotegravir + rilpivirine
Number of subjects: 0
Study 34978890 — intervention group
Group type: COMPARATOR
Intervention: Daily oral dolutegravir/abacavir/lamivudine
Number of subjects: 0
Study 34978890 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting therapy
Number of subjects: 0
Study 34979020 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab (up to 5 cycles, continuous infusion, cycle: 4 weeks on/2 weeks off)
Number of subjects: 110
Study 34979020 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 110
Study 34979115 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGUS (Magnetic Gastrointestinal Universal Septotome) system
Number of subjects: 14
Study 34979117 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy retraction score (CoRS)
Number of subjects: 333
Study 34979117 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal time
Number of subjects: 333
Study 34979118 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution manometry (HRM)
Number of subjects: 87
Study 34979118 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional lumen imaging probe (FLIP)
Number of subjects: 87
Study 34979118 — intervention group
Group type: EXPERIMENTAL
Intervention: Eckardt score (ES)
Number of subjects: 87
Study 34979118 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum esophagogastric junction distensibility (MxEGJD)
Number of subjects: 87
Study 34979118 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal post-POEM EGJ distensibility index (EGJ-DI)
Number of subjects: 87
Study 34979118 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal IRP
Number of subjects: 87
Study 34979118 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal MxEGJD
Number of subjects: 87
Study 34979601 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen section biopsy
Number of subjects: 646
Study 34979601 — intervention group
Group type: COMPARATOR
Intervention: Frozen section biopsy omission
Number of subjects: 646
Study 34979928 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged sigh breath lung recruitment maneuver (LRM)
Number of subjects: 18
Study 34979932 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative ultrasound assessment of gastric content
Number of subjects: 47
Study 34979932 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative ultrasound assessment of gastric volume
Number of subjects: 47
Study 34979970 — intervention group
Group type: EXPERIMENTAL
Intervention: PDI drugs (e.g., Zolpidem, Zopiclone, Bromazepam, Tramadol, Pregabalin)
Number of subjects: 1783
Study 34979970 — intervention group
Group type: EXPERIMENTAL
Intervention: PDI drugs
Number of subjects: 1783
Study 34979983 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone biopsy to assess bone histomorphometry
Number of subjects: 32
Study 34979983 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride activity measurement in lumbar spine
Number of subjects: 32
Study 34979983 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH measurement
Number of subjects: 32
Study 34979983 — intervention group
Group type: EXPERIMENTAL
Intervention: Erosion surfaces measurement
Number of subjects: 32
Study 34979983 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall calcification score
Number of subjects: 32
Study 34980020 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental arms in each cohort
Number of subjects: 6
Study 34980020 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 6
Study 34980038 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with three cycles of carboplatin and paclitaxel
Number of subjects: 0
Study 34980038 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-modality arm (minimally-invasive surgery or radiation alone to 50 Gy)
Number of subjects: 0
Study 34980038 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate de-escalation arm (chemoradiation to 50 Gy with cisplatin)
Number of subjects: 0
Study 34980038 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular dose arm (chemoradiation to 70 Gy with concurrent cisplatin)
Number of subjects: 0
Study 34980055 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal approach plantar plate repair using standard operative instruments
Number of subjects: 10
Study 34980176 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of an adenovirus targeting SNHG15
Number of subjects: 0
Study 34980176 — intervention group
Group type: EXPERIMENTAL
Intervention: SNHG15
Number of subjects: 0
Study 34980185 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance (CMR) using anatomically correct contouring method
Number of subjects: 3206
Study 34980185 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance (CMR)
Number of subjects: 3206
Study 34980199 — intervention group
Group type: EXPERIMENTAL
Intervention: 4D flow CMR parameters in rTOF patients
Number of subjects: 63
Study 34980199 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 63
Study 34980208 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized daily text messaging (SMS/MMS), posts on social media platforms, and online groups
Number of subjects: 642
Study 34980208 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized daily text messaging (SMS/MMS), posts on social media platforms, online groups, and brief technology-mediated health coaching
Number of subjects: 642
Study 34980208 — intervention group
Group type: COMPARATOR
Intervention: Wearable activity tracker, connected scale, and corresponding app alone
Number of subjects: 642
Study 34980208 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SMART 2.0 intervention groups
Number of subjects: 642
Study 34980208 — intervention group
Group type: EXPERIMENTAL
Intervention: Group receiving health coaching
Number of subjects: 642
Study 34980208 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 642
Study 34980220 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular progesterone 40 mg per day from D3 to 8 weeks of gestation if clinical pregnancy is achieved.
Number of subjects: 0
Study 34980220 — intervention group
Group type: COMPARATOR
Intervention: Low serum progesterone group (control).
Number of subjects: 0
Study 34980224 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (50 mg intravenous bolus every 6 hours) and fludrocortisone (50 μg once a day enterally) for 7 days or until discharge from the ICU
Number of subjects: 380
Study 34980224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 380
Study 34980502 — intervention group
Group type: EXPERIMENTAL
Intervention: SSTR2-targeted peptide-radionuclide receptor therapy (PRRT)
Number of subjects: 404
Study 34980502 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 404
Study 34980502 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic neck irradiation
Number of subjects: 404
Study 34980502 — intervention group
Group type: EXPERIMENTAL
Intervention: Dural infiltration at presentation
Number of subjects: 404
Study 34980502 — intervention group
Group type: EXPERIMENTAL
Intervention: Kadish-Morita staging and Dulguerov T-stage
Number of subjects: 404
Study 34980541 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus trastuzumab (arms B&C)
Number of subjects: 1282
Study 34980541 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (arm A)
Number of subjects: 1282
Study 34980577 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine and Nivolumab
Number of subjects: 236
Study 34980577 — intervention group
Group type: COMPARATOR
Intervention: AML with diploid karyotype
Number of subjects: 236
Study 34980577 — intervention group
Group type: COMPARATOR
Intervention: Next Generation Sequencing
Number of subjects: 236
Study 34980597 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg every 2 weeks + cabozantinib 40 mg every day
Number of subjects: 0
Study 34980597 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab 480 mg every 4 weeks + cabozantinib 40 mg every day
Number of subjects: 0
Study 34980611 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Care Path for Living Kidney Donor Candidates
Number of subjects: 122
Study 34980610 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive deep brain stimulation (aDBS)
Number of subjects: 15
Study 34980610 — intervention group
Group type: COMPARATOR
Intervention: Conventional deep brain stimulation (cDBS)
Number of subjects: 15
Study 34980614 — intervention group
Group type: EXPERIMENTAL
Intervention: Fertility Health Screening group (FHS)
Number of subjects: 1200
Study 34980614 — intervention group
Group type: EXPERIMENTAL
Intervention: Fertility Awareness Tools (FAT)
Number of subjects: 1200
Study 34980614 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 1200
Study 34980633 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care C reactive protein (POC CRP) testing, prescription guidance, and safety-netting advice.
Number of subjects: 0
Study 34980633 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 34980909 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentiviral globin gene therapy with reduced-intensity conditioning
Number of subjects: 4
Study 34981068 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Number of subjects: 1181
Study 34981068 — intervention group
Group type: COMPARATOR
Intervention: Placebo control plasma
Number of subjects: 1181
Study 34981077 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamlanivimab 7000 mg
Number of subjects: 317
Study 34981077 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamlanivimab 700 mg
Number of subjects: 317
Study 34981077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317
Study 34981077 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamlanivimab 7000 mg and 700 mg
Number of subjects: 317
Study 34981142 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-90002 (anti-CD47 monoclonal antibody) administered in escalating doses of 0.1-4.0 mg/kg
Number of subjects: 28
Study 34981144 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone (DFP), single 1500 mg dose
Number of subjects: 8
Study 34981300 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated stereotactic radiotherapy (HSRT) with doses of either 27.5 or 30 Gy
Number of subjects: 15
Study 34981300 — intervention group
Group type: EXPERIMENTAL
Intervention: T1c sequence imaging
Number of subjects: 15
Study 34981300 — intervention group
Group type: EXPERIMENTAL
Intervention: T2f sequence imaging
Number of subjects: 15
Study 34981464 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT) for 16 sessions
Number of subjects: 56
Study 34981464 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency-rapid response in binge eating
Number of subjects: 56
Study 34982018 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented Reality (AR) Leaflet
Number of subjects: 12
Study 34982018 — intervention group
Group type: COMPARATOR
Intervention: Traditional Leaflet
Number of subjects: 12
Study 34982055 — intervention group
Group type: EXPERIMENTAL
Intervention: Low heart rate (<65 bpm)
Number of subjects: 1760
Study 34982055 — intervention group
Group type: EXPERIMENTAL
Intervention: High heart rate (≥86 bpm)
Number of subjects: 1760
Study 34982055 — intervention group
Group type: EXPERIMENTAL
Intervention: High heart rate (≥86 bpm) among patients with LVEF ≥50%
Number of subjects: 1760
Study 34982055 — intervention group
Group type: EXPERIMENTAL
Intervention: Low heart rate (<65 bpm) among patients with LVEF <50%
Number of subjects: 1760
Study 34982337 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal perception of child weight status
Number of subjects: 591
Study 34982337 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal perception of child weight status
Number of subjects: 591
Study 34982397 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad-DiaRem score for SG
Number of subjects: 109
Study 34982397 — intervention group
Group type: COMPARATOR
Intervention: Ad-DiaRem score for RYGB
Number of subjects: 109
Study 34982397 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCD score for SG
Number of subjects: 109
Study 34982397 — intervention group
Group type: COMPARATOR
Intervention: ABCD score for RYGB
Number of subjects: 109
Study 34982397 — intervention group
Group type: COMPARATOR
Intervention: Diabetes remission in RYGB group
Number of subjects: 109
Study 34982397 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes duration and glycated haemoglobin
Number of subjects: 109
Study 34982399 — intervention group
Group type: EXPERIMENTAL
Intervention: Contemporary management strategies for acute PE
Number of subjects: 4000
Study 34983109 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile management
Number of subjects: 923
Study 34983109 — intervention group
Group type: COMPARATOR
Intervention: Traditional management
Number of subjects: 923
Study 34983125 — intervention group
Group type: EXPERIMENTAL
Intervention: Male urinary incontinence (UI)
Number of subjects: 4076
Study 34983237 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 224
Study 34983237 — intervention group
Group type: COMPARATOR
Intervention: Women
Number of subjects: 224
Study 34983237 — intervention group
Group type: EXPERIMENTAL
Intervention: Total plaque volume
Number of subjects: 224
Study 34983430 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocyte Distribution Width (MDW) with cutoff of 20
Number of subjects: 402
Study 34983430 — intervention group
Group type: COMPARATOR
Intervention: Procalcitonin (PCT) with cutoff of 0.5 ng/mL
Number of subjects: 402
Study 34983430 — intervention group
Group type: EXPERIMENTAL
Intervention: MDW combined with WBC count
Number of subjects: 402
Study 34983430 — intervention group
Group type: EXPERIMENTAL
Intervention: MDW for predicting sepsis-3 with cutoff of 20
Number of subjects: 402